# Abvc Biopharma, Inc.: overview ABVC · Nasdaq · CIK 1173313 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/abvc.md) · [Financials](/companies/abvc/financials.md) · [Filings](/companies/abvc/filings.md) · [Insiders](/companies/abvc/insiders.md) Latest reported revenue: [−$499.9k](/filings/0001213900-26-023063.md) for Q4 FY2025, three months to 2025-12-31, from the 10-K filed Mar 3, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001213900-26-023063). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [389](/filings/0001213900-26-023062.md) | [2.0 d](/filings/0001213900-26-023063.md) | not reported | not reported | [796](/filings/0001213900-25-104811.md) | [(500) d](/filings/0001213900-26-023063.md) | not reported | not reported | | Gross margin | % | [99.9%](/filings/0001213900-26-023062.md) | [100.0% d](/filings/0001213900-26-023063.md) | not reported | not reported | [100.0%](/filings/0001213900-25-104811.md) | not reported | not reported | not reported | | Operating margin | % | [(77.7%)](/filings/0001213900-26-023062.md) | [(35837.4%) d](/filings/0001213900-26-023063.md) | not reported | not reported | [(246.8%)](/filings/0001213900-26-023062.md) | [439.8% d](/filings/0001213900-26-023063.md) | not reported | not reported | | Net margin | % | [(101.4%)](/filings/0001213900-26-023062.md) | [(37211.3%) d](/filings/0001213900-26-023063.md) | not reported | not reported | [(256.6%)](/filings/0001213900-26-023062.md) | [553.5% d](/filings/0001213900-26-023063.md) | not reported | not reported | | Diluted EPS | $ per share | [(0.03)](/filings/0001213900-26-023062.md) | not reported | [(0.06)](/filings/0001213900-26-058104.md) | [(0.13)](/filings/0001213900-26-088348.md) | [(0.09)](/filings/0001213900-26-023062.md) | not reported | [(0.06)](/filings/0001213900-26-058104.md) | [(0.03)](/filings/0001213900-26-088348.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [356](/filings/0001213900-23-025554.md) | [970](/filings/0001213900-24-022235.md) | [152](/filings/0001213900-25-032118.md) | [510](/filings/0001213900-26-023063.md) | [296](/filings/0001213900-26-023063.md) | | Gross margin | % | [98.6%](/filings/0001213900-23-025554.md) | [70.5%](/filings/0001213900-24-022235.md) | [(98.1%)](/filings/0001213900-25-032118.md) | [99.9%](/filings/0001213900-26-023063.md) | not reported | | Operating margin | % | [(3290.1%)](/filings/0001213900-23-025554.md) | [(1558.5%)](/filings/0001213900-24-022235.md) | [(4439.2%)](/filings/0001213900-25-032118.md) | [(923.3%)](/filings/0001213900-26-023063.md) | [(2416.0%)](/filings/0001213900-26-023063.md) | | Net margin | % | [(3608.5%)](/filings/0001213900-23-025554.md) | [(1693.5%)](/filings/0001213900-24-022235.md) | [(5109.3%)](/filings/0001213900-25-032118.md) | [(962.1%)](/filings/0001213900-26-023063.md) | [(2671.8%)](/filings/0001213900-26-023063.md) | | Diluted EPS | $ per share | [(0.51)](/filings/0001213900-23-025554.md) | [(5.19)](/filings/0001213900-24-022235.md) | [(1.80)](/filings/0001213900-25-032118.md) | [(0.42)](/filings/0001213900-26-023063.md) | [(0.39)](/filings/0001213900-26-023063.md) | | Free cash flow | $k | [(7,615)](/filings/0001213900-23-025554.md) | [(7,518)](/filings/0001213900-24-022235.md) | [(4,208)](/filings/0001213900-25-032118.md) | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/abvc/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $591.7k | 374,499 | | Added +183,925 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $360.4k | 228,042 | | Added +6,873 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $153.8k | 97,363 | | Unchanged | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $115.0k | 72,800 | | Unchanged | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $113.9k | 72,091 | | New +72,091 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $89.2k | 56,442 | | Unchanged | | [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $76.9k | 48,643 | | Added +16,556 | | [XTX Topco Ltd](/funds/1828301.md) | 2026-06-30 | $76.3k | 48,276 | | New +48,276 | | [PANAGORA ASSET MANAGEMENT INC](/funds/883677.md) | 2026-06-30 | $58.0k | 36,682 | | New +36,682 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $53.9k | 34,123 | | Added +32,352 | ## Recent filings [All 687 filings](/companies/abvc/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-29 | 12:22 ET | [DEF 14A](/filings/0001213900-26-104509.md) | Proxy statement, period 2026-10-28 | 0001213900-26-104509 | | 2026-08-27 | 08:30 ET | [8-K](/filings/0001213900-26-094152.md) | 1.01 Entry into a material agreement; 2.01 Completion of an acquisition or disposition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-094152 | | 2026-08-12 | 16:06 ET | [10-Q](/filings/0001213900-26-088348.md) | Quarterly report, period 2026-06-30 | 0001213900-26-088348 | | 2026-08-12 | 11:50 ET | [8-K/A](/filings/0001213900-26-088165.md) | 8.01 Other events | 0001213900-26-088165 | | 2026-08-04 | 21:12 ET | [8-K](/filings/0001213900-26-084846.md) | 8.01 Other events | 0001213900-26-084846 | | 2026-07-02 | 16:01 ET | [8-K](/filings/0001213900-26-074949.md) | 4.01 Change of auditor; 9.01 Financial statements and exhibits | 0001213900-26-074949 | | 2026-05-18 | 07:22 ET | [10-Q](/filings/0001213900-26-058104.md) | Quarterly report, period 2026-03-31 | 0001213900-26-058104 | | 2026-03-27 | 16:05 ET | [8-K](/filings/0001213900-26-035499.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001213900-26-035499 | | 2026-03-05 | 16:29 ET | [DEF 14A](/filings/0001213900-26-024122.md) | Proxy statement, period 2026-03-26 | 0001213900-26-024122 | | 2026-03-03 | 16:20 ET | [10-K](/filings/0001213900-26-023063.md) | Annual report, period 2025-12-31 | 0001213900-26-023063 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-023063.md), filed Mar 3, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1173313 - Tickers: ABVC, ECOC - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: NV - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.